WHO Pharmaceuticals Newsletter 1998, No. 09&10
(1998; 23 pages)
Table des matières
Fermer ce répertoireRegulatory decisions
Afficher le documentAlbumin (human) B batches withdrawn: increase in aluminium level: Austria
Afficher le documentAstemizole - warning concerning arrhythmias: Brazil
Afficher le documentChlormezanone - withdrawn: Zimbabwe
Afficher le documentChlorzoxazone - warning: hepatotoxicity: Chile
Afficher le documentCidofovir - adverse reactions: nephrotoxicity, uveitis/iritis and hearing loss: Gilead Sciences, USA
Afficher le documentFenfluramine and dexfenfluramine - temporary suspension: Brazil
Afficher le documentFenfluramine and dexfenfluramine - warning concerning adverse reactions: Chile
Afficher le documentIonic contrast media - notice of withdrawal: Germany
Afficher le documentLaxatives containing aloe, bisacodyl, cascara sagrada and senna - proposed reclassification: USA
Afficher le documentMeloxicam - data sheet revised: gastrointestinal and skin reactions: UK
Afficher le documentMetamizole sodium - withdrawn due to agranulocytosis: Zimbabwe
Afficher le documentMibefradil - suspended: Germany
Afficher le documentNifedipine - re-approved in myocardial infarction: New Zealand
Afficher le documentPsorial ointment - sales prohibited: undeclared cortisone ingredients: Sweden
Afficher le documentPsorigon cream & lotion - withdrawn: undeclared cortisone ingredients: Germany, USA
Afficher le documentTiclopidine - revised data sheet: thrombotic thrombocytopenic purpura: Roche, USA
Afficher le documentTroglitazone - revised instructions for use: Parke-Davis, USA
Afficher le documentVitamin A and betacarotene - labelling claim prohibited: USA
Ouvrir ce répertoire et afficher son contenuDrug surveillance
Ouvrir ce répertoire et afficher son contenuNew developments
Ouvrir ce répertoire et afficher son contenuMedical devices
Ouvrir ce répertoire et afficher son contenuGeneral information
Ouvrir ce répertoire et afficher son contenuMedication errors
Ouvrir ce répertoire et afficher son contenuVeterinary medicine
 

Laxatives containing aloe, bisacodyl, cascara sagrada and senna - proposed reclassification: USA

United States of America. In the context of its review of over-the-counter laxative ingredients, the Food and Drug Administration has proposed to reclassify the stimulant laxative ingredients aloe, bisacodyl, cascara sagrada and senna (including sennosides) from Category I (generally recognized as safe and effective) to Category III (more data needed).

The agency reviewed available data concerning these products, and concluded that carcinogenicity data are insufficient.

The full text is available on request.

[See also Pharmaceuticals Newsletter Nos. 5&6, May & June, 1&2, January & February 1998, Nos 11&12, November & December 1997, DRS Information Exchange Alert No. 65 of 7 October 1997]

Reference: Federal Register 63(118): 33592-33595 (1998).

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013